Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in children and young adults: a systematic review and meta-analysis

Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in children and young adults: a systematic review and meta-analysis

Purpose Sodium glucose cotransporter-2 inhibitors (SGLT2i) have been evaluated in children with type 2 diabetes mellitus (T2DM), type 1 diabetes mellitus (T1DM), and several other nondiabetic conditions. Potential tolerability issues have prevented the routine use of SGLT2i in children with diabetes...

Bibliografski detalji
Glavni autori:	Lakshmi Nagendra, Deep Dutta, Harish Bukkasagar Girijashankar, Deepak Khandelwal, Tejal Lathia, Meha Sharma
Format:	Članak
Jezik:	English
Izdano:	Korean Society of Pediatric Endocrinology 2024-04-01
Serija:	Annals of Pediatric Endocrinology & Metabolism
Teme:	empagliflozin dapaglifozin systematic review child type 2 diabetes mellitus type 1 diabetes mellitus
Online pristup:	http://e-apem.org/upload/pdf/apem-2346162-081.pdf

Slični predmeti

Highly selective sodium glucose cotransporter type 2 inhibitor empagliflozin neuroprotective potential in chronic brain dyscirculation
od: Оksana S. Fuks, i dr.
Izdano: (2023-07-01)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial
od: Takashi Kadowaki, i dr.
Izdano: (2019-05-01)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
od: Simes BC, i dr.
Izdano: (2019-10-01)

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
od: Mathew John, i dr.
Izdano: (2016-01-01)

Use of sodium-glucose co-transporter-2 inhibitors from clinical trial results to practical application in Russia
od: D. A. Lebedev, i dr.
Izdano: (2018-09-01)

Efficacy and Safety of Empagliflozin as Add-On Therapy in Patients of Type-2 Diabetes Mellitus
od: Nauman Wazir, i dr.
Izdano: (2022-01-01)

Sodium-Glucose Cotransporter 2 Inhibitors and Management of Refractory Hypomagnesemia Without Overt Urinary Magnesium Wasting: A Report of 2 Cases
od: Chintan V. Shah, MD, i dr.
Izdano: (2022-10-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
od: Moritz Mahling, i dr.
Izdano: (2019-08-01)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
od: Reed JW
Izdano: (2016-10-01)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
od: Ahmadieh H, i dr.
Izdano: (2017-05-01)

Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy
od: Edoardo Mannucci, i dr.
Izdano: (2022-12-01)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
od: Asima Khan, i dr.
Izdano: (2022-08-01)

Inhibitors of the sodium-glucose transporter type 2 and new possibilities for managing vascular age in patients with type 2 diabetes mellitus
od: I. Sh. Khalimov, i dr.
Izdano: (2021-09-01)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
od: M. Arow, i dr.
Izdano: (2020-01-01)

Short-Term Effect of Sodium Glucose Co – Transporter 2 Inhibitors on Routine Laboratory Examinations
od: Osman İnan, i dr.
Izdano: (2022-07-01)

Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin
od: Haroon Aziz, i dr.
Izdano: (2023-06-01)

Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity
od: Sebahat Ulusan, i dr.
Izdano: (2023-05-01)

Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
od: Sanjay Kalra, i dr.
Izdano: (2015-01-01)

Improvements of myocardial strain and work in diabetes patients with normal ejection fraction after empagliflozin treatment
od: Xueqing Cheng, i dr.
Izdano: (2024-07-01)

Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis
od: Deep Dutta, i dr.
Izdano: (2021-04-01)

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
od: Sanjay Kalra, i dr.
Izdano: (2015-01-01)

Cardiovascular death risk reduction in type 2 diabetes patients with confirmed cardiovascular diseases
od: Е. V. Shlyakhto, i dr.
Izdano: (2018-09-01)

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
od: A. V. Simanenkova, i dr.
Izdano: (2021-07-01)

Current possibilities of influencing the main cardiovascular risk factors in patients with type 2 diabetes mellitus
od: O.Ya. Kobrynska, i dr.
Izdano: (2022-12-01)

Evaluation of the Effect of Empagliflozin Therapy on T Helper 22 Cell-Related Factors in Patients with Type 2 Diabetes Mellitus
od: Hamid Moghimi, i dr.
Izdano: (2021-03-01)

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
od: Agnes Bosch, i dr.
Izdano: (2019-03-01)

Optimized treatment of elderly patients with type 2 diabetes mellitus and hypertension in general practice
od: Yu.M. Kazakov, i dr.
Izdano: (2024-04-01)

The role of sodium-glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes: from clinical research to real practice
od: I. V. Misnikova, i dr.
Izdano: (2020-12-01)

The effect of empagliflozin (sodium–glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study
od: Jinmei Tan, i dr.
Izdano: (2024-10-01)

Sodium–glucose cotransporter inhibitors as add‐on therapy in addition to insulin for type 1 diabetes mellitus: A meta‐analysis of randomized controlled trials
od: Hailan Zou, i dr.
Izdano: (2021-04-01)

SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS DURING THE MONTH OF RAMADAN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A TERTIARY CARE CENTRE IN KARACHI, PAKISTAN
od: Aisha Sheikh, i dr.
Izdano: (2021-11-01)

Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis
od: Deep Dutta, i dr.
Izdano: (2023-01-01)

Is calorie restriction with sodium-glucose cotransporter 2 inhibitor dapagliflozin a better option for type 2 diabetes mellitus management?
od: Ruby Dhar, i dr.
Izdano: (2025-03-01)

Evaluation of sodium‐glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics
od: Yi‐Fang Weng, i dr.
Izdano: (2023-04-01)

The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
od: Bo Xu, i dr.
Izdano: (2022-05-01)

A case of sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis complicated by concurrent subacute thyroiditis
od: Miyu Kinoshita, i dr.
Izdano: (2022-09-01)

An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients
od: Wang Y, i dr.
Izdano: (2016-07-01)

The Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Uric Acid in Type 2 Diabetes Mellitus
od: Dong M, i dr.
Izdano: (2023-02-01)

Flozins, inhibitors of type 2 renal sodium-glucose co-transporter – not only antihyperglycemic drugs
od: Mizerski Grzegorz, i dr.
Izdano: (2015-09-01)

Administration of sodium-glucose cotransporter-2 inhibitors in kidney transplant patients with diabetes: a systematic review and meta-analysis
od: Hamidreza Khodabandeh, i dr.
Izdano: (2023-09-01)